Regazzi Luca, Martinelli Silvia, Rizzo Federica, Tamburrini Enrica, Salvo Pierluigi Francesco, Bosello Silvia Laura, Landi Francesco, Sica Simona, Spadea Antonietta, Pascucci Domenico, Laurenti Patrizia
Hygiene Unit, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.
Department of Biomedicine and Prevention, Tor Vergata University of Rome, 00133 Roma, Italy.
Vaccines (Basel). 2025 Aug 8;13(8):843. doi: 10.3390/vaccines13080843.
: Immunocompromised and clinically fragile individuals are at increased risk of herpes zoster (HZ), but vaccine uptake remains low due to organizational barriers and vaccine hesitancy (VH). This study aimed to evaluate the impact of a multidisciplinary hospital-based counseling model on attitudes toward the recombinant adjuvanted zoster vaccine (RZV). The primary objective was to assess changes in VH over time using the Vaccination Attitudes Examination (VAX) scale; secondary objectives included identifying factors associated with VH, evaluating vaccine safety, and monitoring post-vaccination HZ incidence. : A prospective cohort study was conducted in a large research hospital in Rome, in collaboration with the Local Health Authority. Eligible patients were offered individualized counseling and administered two doses of the RZV. VH was assessed using the 12-item VAX scale at baseline and at one-year follow-up. Multivariable linear regression analysis was performed to investigate associations between baseline characteristics and VH scores. : Between July 2022 and July 2023, 178 patients were enrolled, of whom 90 completed the one-year follow-up. Baseline VH was moderate (mean VAX: 2.291/6.000); higher scores were significantly associated with younger age, female sex, and rheumatologic disease ( < 0.05). After the intervention, VAX scores improved significantly across all subscales, particularly in trust in vaccine safety and benefits ( < 0.001). RZV was well tolerated; adverse events were mild and transient. Breakthrough HZ occurred in 3.33% of cases during follow-up. : A multidisciplinary hospital-based model effectively improved vaccine attitudes and acceptance in fragile patients. Tracking VH over time with validated tools offers insights for scaling targeted interventions in high-risk groups.
免疫功能低下和临床脆弱的个体患带状疱疹（HZ）的风险增加，但由于组织障碍和疫苗犹豫（VH），疫苗接种率仍然很低。本研究旨在评估基于医院的多学科咨询模式对重组佐剂带状疱疹疫苗（RZV）态度的影响。主要目标是使用疫苗接种态度检查（VAX）量表评估VH随时间的变化；次要目标包括确定与VH相关的因素、评估疫苗安全性以及监测接种后HZ的发病率。：在罗马的一家大型研究医院与地方卫生当局合作开展了一项前瞻性队列研究。符合条件的患者接受了个性化咨询并接种了两剂RZV。在基线和一年随访时使用12项VAX量表评估VH。进行多变量线性回归分析以研究基线特征与VH评分之间的关联。：在2022年7月至2023年7月期间，共招募了178名患者，其中90名完成了一年随访。基线VH为中等水平（平均VAX：2.291/6.000）；较高的分数与年轻、女性和风湿性疾病显著相关（<0.0 .05）。干预后，所有子量表的VAX评分均显著改善，尤其是在对疫苗安全性和益处的信任方面（<0.001）。RZV耐受性良好；不良事件轻微且短暂。随访期间3.33%的病例发生了突破性HZ。：基于医院的多学科模式有效地改善了脆弱患者对疫苗的态度和接受度。使用经过验证的工具跟踪VH随时间的变化，为扩大高危人群的针对性干预措施提供了见解。
